Massive Bio to Unveil Reticulum Nexus™ as the AI Operating System for Oncology Access at ASCO 2026
Summary
Massive Bio will unveil Reticulum Nexus at ASCO 2026 as its AI operating system for oncology access. The platform brings together patient engagement, record ingestion, eligibility interpretation, trial pre-screening, referral orchestration, biomarker intelligence, site activation, navigation, and follow-up into one workflow. Massive Bio positions the system as infrastructure for coordinating real-world oncology access rather than a standalone chatbot or dashboard. The company says the launch builds on prior collaborations, regulatory listings, and prospective evidence showing faster trial matching at scale.
Classifications
industries
HealthTech
applications
Web and Content Management
AskAI Classifications
Labels
AI Software
SaaS
Developer Tools
Linked Companies
OpenAI
$25M to $50M
Massive Bio
$1M to $5M